Pfizer's gross profit margin for the second quarter of its fiscal year 2012 is essentially unchanged when compared to the same period a year ago. Even though sales decreased, the net income has increased, representing an increase to the bottom line. Pfizer has average liquidity. Currently, the Quick Ratio is 1.21 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
During the same period, stockholders' equity ("net worth") has decreased by 10.09% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
The current P/E ratio indicates a discount compared to an average of 21.78 for the Pharmaceuticals industry and a premium compared to the S&P 500 average of 16.49. To use another comparison, its price-to-book ratio of 2.28 indicates valuation on par with the S&P 500 average of 2.28 and a significant discount versus the industry average of 5.54. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, Pfizer proves to trade at a discount to investment alternatives within the industry.